Objective-Liver X receptor (LXR) activators decrease atherosclerosis in mice. LXR activators (1) directly upregulate genes involved in reverse cholesterol transport and (2) exert anti-inflammatory effects mediated by transrepression of nuclear factor-κB target genes. We investigated whether myeloid cell deficiency of ATP-binding cassette transporters A1 and G1 (ABCA1/G1), principal targets of LXR that promote macrophage cholesterol efflux and initiate reverse cholesterol transport, would abolish the beneficial effects of LXR activation on atherosclerosis. Approach and Results-LXR activator T0901317 substantially reduced inflammatory gene expression in macrophages lacking ABCA1/G1. Ldlr −/− mice were transplanted with Abca1
L iver X receptors (LXR) are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily. 1 LXR-α is expressed in the liver, adipose, intestine, kidney, and macrophages, whereas expression of LXR-β is nearly ubiquitous. 2 LXRs are activated by oxysterols formed in response to increased intracellular cholesterol levels. 3 Synthetic compounds such as T0901317 (T0) and GW3965 (GW) have also been established as active oral LXR agonists. 4, 5 Further investigation into the role of LXR in cholesterol homeostasis led to the discovery that synthetic LXR activators decrease atherosclerosis in multiple mouse models, including Apoe −/− and Ldlr −/− mice. [6] [7] [8] Two principal properties of LXR activators that may contribute to their antiatherogenic effects are (1) direct upregulation of genes involved in macrophage cholesterol efflux and reverse cholesterol transport (RCT) such as the ATP-binding cassette transporters A1 and G1 (ABCA1 and ABCG1) 9 and (2) anti-inflammatory effects mediated by a distinct molecular mechanism involving SUMOylation of LXR and transrepression of nuclear factor-κB (NF-κB) target genes. 10 Although (1) is known to be antiatherogenic, the role of (2) in mediating antiatherogenic effects of LXR activators has not been explored. Therefore, we investigated whether myeloid or macrophage deficiency of ABCA1 and ABCG1, 2 principal targets of LXR as well as key components of the cholesterol efflux pathway, would abolish the beneficial effects of LXR activation on atherosclerosis.
Results

LXR Activation Decreases Inflammatory Gene Expression in Lipopolysaccharide-Stimulated Macrophages Lacking ABCA1 and ABCG1 In Vitro
We have shown that the ability of LXR activator to increase cholesterol efflux to HDL or apoA1 is abolished in macrophages lacking ABCA1 and ABCG1. 11, 12 To determine whether LXR activator treatment retained its anti-inflammatory effects, we treated LysmCreAbca1 Abcg1 fl/fl macrophages indicating that its anti-inflammatory effects occur independent of ABCA1/G1 expression ( Figure 1 
Abcg1
fl/fl macrophages ( Figure 1) ; however, the effect was less pronounced, and statistical significance was only reached for Mip-1α (P<0.05). This is consistent with the known antiinflammatory effects of LXR activators, which have been demonstrated in vitro and in vivo. 10, 13, 14 The more pronounced anti-inflammatory effects in macrophages lacking ABCA1/G1 may reflect their higher baseline inflammatory gene expression. 
LXR Activation Decreases Atherosclerosis in
Abcg1
−/− bone marrow (BM) and fed a Western-type diet (WTD) for 6 weeks supplemented with or without the LXR activator T0 (10 mg/kg). Reconstitution of the BM was >90% (results not shown). Cholesterol and triglyceride (TG) levels were measured after 3 weeks of WTD feeding with or without T0 ( Figure I in the online-only Data Supplement). BM Abca1/ g1 deficiency decreased plasma cholesterol and TG levels by 64% and 31%, respectively (both P<0.001), which was mainly 
−/− BM 15 and may partly reflect increased uptake of LDL by a non-Ldlr-dependent mechanism in the expanded myeloid cell compartment of these mice as has been shown in humans with myeloproliferative diseases. 16 We also found an ≈82% decrease in mRNA expression of sterol regulatory element-binding protein-1c in the liver of Ldlr In the control group, the LXR activator did not affect lesion area ( 
−/− bone marrow. Inflammatory nuclei in the adventitia of hematoxylin and eosin-stained sections were quantified. n=6 to 9 mice per group; **P<0.01.
macrophage Abca1/g1 deficiency. We used the GW compound to activate LXR, which has been reported to induce lesser hepatic steatosis than the T0 compound, 19 and does not exhibit the off-target effects of T0 such as activation of the farnesoid X receptor, 20 the pregnane X receptor, 19 and the retinoic acid receptor-related orphan receptor. 21 After 12 weeks of WTD, mice were euthanized, and atherosclerosis was assessed in the aortic root. Macrophage Abca1/g1 deficiency did not affect atherosclerotic lesion size ( Figure 4A and Figure X in the online-only Data Supplement), likely because of the ≈50% decreased cholesterol levels, as we observed previously in this model. 11 Under these conditions, the control group developed more advanced lesions than the Figure 4A ). Macrophage Abca1/g1 deficiency increased plasma monocyte chemoattractant protein 1 (MCP-1) levels (3.7-fold; P<0.001; Figure 4C ). GW treatment decreased plasma MCP-1 in mice lacking Abca1/g1 in macrophages ( Figure 4C) , further substantiating the observation that the antiatherogenic effect of LXR activation may reflect its anti-inflammatory effects.
Discussion
It is well known that LXR activation causes increased expression of genes involved in cholesterol efflux and RCT such as ABCA1 and ABCG1 in macrophages. 9 A therapeutic agent with the ability to increase cholesterol efflux would have obvious positive implications for the treatment of atherosclerosis because it would decrease the number of lipid-laden macrophages or foam cells embedding themselves into the artery wall. Indeed LXR activators have been shown to decrease atherosclerosis in multiple mouse models, and this has been assumed to be mainly because of its effects on cholesterol efflux and reverse cholesterol transport. [6] [7] [8] LXR also mediates a distinct mechanism of transrepression of the expression of inflammatory genes. 10 When LXR becomes bound by a ligand, it can then be conjugated to a SUMO protein. This process targets the SUMOylated LXR to the promoters of NF-κB target genes where they prevent the signal-dependent removal of corepressor complexes required for transcriptional activation. 10 Thus, inflammatory genes downstream of NF-κB are maintained in a repressed state. 10 Previous studies have shown beneficial effects of LXR activator treatment in skin inflammation models, 22 rheumatoid arthritis models, 23 and hepatic injury caused by endotoxemia. 24 However, the role of inflammatory gene suppression in atherosclerosis has not been addressed.
ABCA1 and ABCG1 are important targets of LXR activation as well as key players in macrophage cholesterol efflux and initiation of RCT. 9 We showed that the ability of LXR activator to increase cholesterol efflux to apoA1 and HDL was abolished in Abca1/g1-deficient macrophages, 11 but that antiinflammatory effects were actually increased in these cells (Figure 1 ). In the absence of ABCA1 and ABCG1, LXR activation by T0 exerted potent antiatherosclerotic effects, reducing early lesion area, complexity, and inflammation (Figure 2) . In a longer term study, LXR activation by GW decreased lesion size and proatherogenic plasma MCP-1 levels in Ldlr −/− mice with macrophage Abca1/g1 deficiency (Figure 4) . Our findings thus suggest that the antiatherosclerotic effects of LXR activation in macrophage and BM Abca1/g1 deficiency were because of anti-inflammatory effects of LXR presumably mediated by the well-established transrepression mechanism. 10, 14 This interpretation was supported by the marked decrease in inflammatory nuclei in the adventitia, and myocardium of Abca1 
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−/− BM, and suggests that the effects of LXR activators on lesion inflammation and complexity may be at least as important as their effects on macrophage foam cell formation. Whereas we also observed increased inflammation in macrophage Abca1/g1 deficiency compared with controls ( Figure 4C ), the atherosclerotic lesion complexity was not more advanced than in controls ( Figure 4B ), likely reflecting the difference in plasma cholesterol levels between these 2 groups.
Several other potential explanations for our findings need to be considered. LXR activation has been shown to increase expression of apoptosis inhibitor expressed by macrophages (AIM; also called Spα or Api6), 25, 26 which supports survival of macrophages in response to apoptosis-inducing stimuli, 27 such as oxidized lipids. 28 As a consequence AIM
mice show decreased atherogenesis. 28 Because LXR treatment reduced atherogenesis in BM and macrophage Abca1/g1 deficiency in our study, it is unlikely that this effect was mediated by AIM.
LXR has multiple gene targets in addition to ABCA1 and ABCG1 that may affect cholesterol homeostasis, including inducible degrader of the Ldlr (IDOL), a molecule that acts to suppress LDL uptake. 29 31 This could reflect beneficial effects on expression of ABCA1 and ABCG1 in vascular endothelial cells. 32 LXR activators also induce hepatic ABCG5/8 33 and seem to stimulate RCT at the level of the small intestine 34 and such effects cannot be excluded in our study. However, studies in isolated macrophages 11, 12 and of macrophage RCT in vivo 35 indicate a major role of ABCA1 and ABCG1 in cholesterol efflux and initiation of RCT from macrophages. Thus, it seems improbable that stimulating cholesterol flux across the liver or intestine would lead to increased cholesterol removal from macrophage foam cells in the absence of upregulating the initial step of macrophage reverse cholesterol transport.
In addition to its beneficial effects, LXR activators have also been shown to induce expression of lipogenic genes and cause hepatic steatosis. 36 An additional potential concern is that LXR activators may induce hepatic IDOL expression leading to reduced levels of LDLrs and increased plasma LDL levels. 29, 37 Because we have shown the anti-inflammatory effects of LXR are of key importance to its antiatherosclerotic effects in vivo, independent of the ABCA1/G1-mediated cholesterol efflux pathway, it should be possible to develop selective LXR activators that mediate inflammatory transrepression without direct targeting of cholesterol efflux, IDOL, and lipogenic genes. These could act as antiatherogenic agents without inducing the adverse effect of fatty liver. Indeed compounds that have selective anti-inflammatory effects with minimal induction of lipogenic gene expression in cultured hepatocytes have been developed, 38 but their role in treating atherosclerosis has not yet been assessed. Our studies suggest that LXR activators selective for their transrepressive effects should be further developed and tested for effects on atherosclerosis, especially in models of advanced, complex disease. 
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